Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Johns Hopkins University
Study ID
NCT07349758
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • HIV Prevention
  • Healthy Volunteer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mg — DRUG
    One-time dose of two F/TAF tablets

Study Details

The goal of this study is to evaluate the pharmacokinetics of a one-time dosing of two F/TAF tablets over a 14-day period.

Key Dates

Start date
Jan 6, 2026
Status verified
Feb 2026
Primary completion
Jan 1, 2027
Completion
Jan 1, 2028

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: F/TAF dosing
    Received one-time dosing of two F/TAF tablets

Primary Outcome Measure

Intracellular tenofovir-diphosphate concentrations (fmol/10^6) [ Time Frame: 168 hours ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Johns Hopkins University School of MedicineBaltimoreMaryland21287
Jennifer Hoffmann, CRNP
[email protected]
410-955-1318
Pooja Akoijam, MD
[email protected]
410-955-1201

Find similar trials in Baltimore, MD

By research site
Johns Hopkins University School of Medicine· Baltimore, MD

Related Studies